Id |
Subject |
Object |
Predicate |
Lexical cue |
T23 |
0-15 |
Sentence |
denotes |
1 Introduction |
T24 |
16-221 |
Sentence |
denotes |
The emergence of novel coronavirus, officially known as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has presented an unprecedented challenge for the healthcare community across the world. |
T25 |
222-426 |
Sentence |
denotes |
High infectivity, ability to get transmitted even during asymptomatic phase and relatively low virulence have resulted in rapid transmission of this virus beyond geographic regions, leading to a pandemic. |
T26 |
427-571 |
Sentence |
denotes |
The first case of this disease, known as coronavirus disease 2019 (COVID-2019), occurred on December 8, 2019 in the Hubei province of China [1]. |
T27 |
572-814 |
Sentence |
denotes |
Since then, within a short span of just over 3 months, the infection has spread to 177 countries/area/territories across the world, with 266073 confirmed cases and 11184 deaths (World Health Organization statistics as on March 21, 2020) [2] . |
T28 |
815-880 |
Sentence |
denotes |
Table 1 Cardiovascular complications in coronavirus disease 2019. |
T29 |
881-912 |
Sentence |
denotes |
Manifestation Incidence Remarks |
T30 |
913-1111 |
Sentence |
denotes |
Acute cardiac injury∗ (most commonly defined as elevation of cardiac troponin I above 99th percentile upper reference limit) 8–12% on average [10] • Most commonly reported cardiovascular abnormality |
T31 |
1112-1187 |
Sentence |
denotes |
• Can result from any of the following mechanisms-•Direct myocardial injury |
T32 |
1188-1210 |
Sentence |
denotes |
•Systemic inflammation |
T33 |
1211-1252 |
Sentence |
denotes |
•Myocardial oxygen demand supply mismatch |
T34 |
1253-1274 |
Sentence |
denotes |
•Acute coronary event |
T35 |
1275-1286 |
Sentence |
denotes |
•Iatrogenic |
T36 |
1287-1320 |
Sentence |
denotes |
• Strong adverse prognostic value |
T37 |
1321-1458 |
Sentence |
denotes |
Acute coronary event Not reported, but appears to be low Potential mechanisms-• Plaque rupture due to inflammation/increased shear stress |
T38 |
1459-1512 |
Sentence |
denotes |
• Aggravation of pre-existing coronary artery disease |
T39 |
1513-1679 |
Sentence |
denotes |
Left ventricular systolic dysfunction Not reported Any of the causes of myocardial dysfunction mentioned above can lead to acute left ventricular systolic dysfunction |
T40 |
1680-1884 |
Sentence |
denotes |
Heart failure Reported in one study- 52% in those who died, 12% in those who recovered and were discharged [5] • Any of the causes of myocardial dysfunction mentioned above can lead to acute heart failure |
T41 |
1885-2003 |
Sentence |
denotes |
• Increased metabolic demand of a systemic disease can cause acute decompensation of pre-existing stable heart failure |
T42 |
2004-2158 |
Sentence |
denotes |
Arrhythmia 16.7% overall; 44.4 in severe illness, 8.9% in mild cases [8] Both tachyarrhythmia and bradyarrhythmia can occur but exact nature not described |
T43 |
2159-2264 |
Sentence |
denotes |
Potential long-term consequences Too early to assess Too early to ascertain for coronavirus disease 2019. |
T44 |
2265-2473 |
Sentence |
denotes |
However, patients recovering from a similar earlier illness- Severe Acute Respiratory Syndrome- continued to have long-term abnormalities of lipid and glucose metabolism and of cardiovascular homeostasis [12] |
T45 |
2474-2704 |
Sentence |
denotes |
∗ Acute cardiac injury is a non-specific term with significant overlap with other cardiovascular manifestations; however, it is listed here because of how reporting has been done in most of the studies on coronavirus disease 2019. |
T46 |
2705-2898 |
Sentence |
denotes |
Respiratory involvement, presenting as mild flulike illness to potentially lethal acute respiratory distress syndrome or fulminant pneumonia, is the dominant clinical manifestation of COVID-19. |
T47 |
2899-3053 |
Sentence |
denotes |
However, much like any other respiratory tract infection, pre-existing cardiovascular disease (CVD) and CV risk factors enhance vulnerability to COVID-19. |
T48 |
3054-3149 |
Sentence |
denotes |
Further, COVID-19 can worsen underlying CVD and even precipitate de novo cardiac complications. |
T49 |
3150-3259 |
Sentence |
denotes |
This review is aimed at providing overview of various CV manifestations in patients presenting with COVID-19. |
T50 |
3260-3384 |
Sentence |
denotes |
The impact of pre-existing CVD and new onset cardiac complications on clinical outcomes in these patients is also discussed. |
T51 |
3385-3679 |
Sentence |
denotes |
Since our understanding on this subject is only evolving at this stage, the information contained in the subsequent text is based mainly on the limited early experience with COVID-19 and learnings from the previous coronavirus illnesses, namely SARS and Middle-East Respiratory Syndrome (MERS). |
T52 |
3681-3698 |
Sentence |
denotes |
2 Search methods |
T53 |
3699-3924 |
Sentence |
denotes |
A literature search was done using PubMed and Google search engines for original and review articles, advisories from professional societies, and expert commentaries published since the onset of the current COVID-19 epidemic. |
T54 |
3925-4096 |
Sentence |
denotes |
Search terms “COVID-19” and “coronavirus” were used in combination with “cardiac”, “cardiovascular”, “arrhythmia”, “myocardial infarction”, “troponin” and “heart failure”. |
T55 |
4097-4183 |
Sentence |
denotes |
Relevant cross-references for previous studies about SARS and MERS were also reviewed. |
T56 |
4185-4215 |
Sentence |
denotes |
2.1 Pathogenic considerations |
T57 |
4216-4279 |
Sentence |
denotes |
SARS-CoV-2 is caused by a novel enveloped RNA beta-coronavirus. |
T58 |
4280-4509 |
Sentence |
denotes |
Seven species of these beta-coronaviruses are known to cause human infections, with four mainly causing mild flulike symptoms and the remaining three resulting in potentially fatal illnesses (SARS, MERS and the ongoing COVID-19). |
T59 |
4510-4628 |
Sentence |
denotes |
Although respiratory tract is the primary target for SARS-CoV-2, CV system may get involved in several different ways. |
T60 |
4629-4718 |
Sentence |
denotes |
Following are the common mechanisms responsible for CV complications in COVID-19 [3,4]-1. |
T61 |
4720-4907 |
Sentence |
denotes |
Direct myocardial injury- SARS-CoV-2 enters human cells by binding to angiotensin-converting enzyme 2 (ACE2), a membrane bound aminopeptidase which is highly expressed in heart and lungs. |
T62 |
4908-5035 |
Sentence |
denotes |
ACE2 plays an important role in neurohumoral regulation of CV system in normal health as well as in various disease conditions. |
T63 |
5036-5173 |
Sentence |
denotes |
The binding of SARS-CoV-2 to ACE2 can result in alteration of ACE2 signaling pathways, leading to acute myocardial and lung injury [3,4]. |
T64 |
5174-5176 |
Sentence |
denotes |
2. |
T65 |
5178-5385 |
Sentence |
denotes |
Systemic inflammation- More severe forms of COVID-19 are characterized by acute systemic inflammatory response and cytokine storm, which can result in injury to multiple organs leading to multiorgan failure. |
T66 |
5386-5506 |
Sentence |
denotes |
Studies have shown high circulatory levels of proinflammatory cytokines in patients with severe/critical COVID-19 [5,6]. |
T67 |
5507-5509 |
Sentence |
denotes |
3. |
T68 |
5511-5772 |
Sentence |
denotes |
Altered myocardial demand-supply ratio- Increased cardiometabolic demand associated with the systemic infection coupled with hypoxia caused by acute respiratory illness can impair myocardial oxygen demand-supply relationship and lead to acute myocardial injury. |
T69 |
5773-5775 |
Sentence |
denotes |
4. |
T70 |
5777-5982 |
Sentence |
denotes |
Plaque rupture and coronary thrombosis- Systemic inflammation as well as increased shear stress due to increased coronary blood flow can precipitate plaque rupture resulting in acute myocardial infarction. |
T71 |
5983-6064 |
Sentence |
denotes |
Prothrombotic milieu created by systemic inflammation further increases the risk. |
T72 |
6065-6067 |
Sentence |
denotes |
5. |
T73 |
6069-6246 |
Sentence |
denotes |
Adverse effects of various therapies- Various antiviral drugs, corticosteroids and other therapies aimed at treating COVID-19 can also have deleterious effects on the CV system. |
T74 |
6247-6249 |
Sentence |
denotes |
6. |
T75 |
6251-6420 |
Sentence |
denotes |
Electrolyte imbalances- Electrolyte imbalances can occur in any critical systemic illness and precipitate arrhythmias, esp. in patients with underlying cardiac disorder. |
T76 |
6421-6559 |
Sentence |
denotes |
There is particular concern about hypokalemia in COVID-19, due to interaction of SARS-CoV-2 with renin-angiotensin-aldosterone system [7]. |
T77 |
6560-6624 |
Sentence |
denotes |
Hypokalemia increases vulnerability to various tachyarrhythmias. |
T78 |
6626-6667 |
Sentence |
denotes |
2.1.1 Role of underling CV comorbidities |
T79 |
6668-6839 |
Sentence |
denotes |
The patients with pre-existing CVD appear to have heightened vulnerability to develop COVID-19 and tend to have more severe disease with worse clinical outcomes [1,4,6,8]. |
T80 |
6840-6992 |
Sentence |
denotes |
Various CV risk factors also adversely affect porgnosis of these patients, although they do not seem to increase likleihood of developing the infection. |
T81 |
6993-7203 |
Sentence |
denotes |
A meta-analysis of six published studies from China including 1527 patients with COVID-19 reported 9.7%, 16.4% and 17.1% prevalence of diabetes, cardio-cerebrovascular disease and hypertension respectively [4]. |
T82 |
7204-7392 |
Sentence |
denotes |
Although the prevalence of diabetes and hypertension in this cohort was same as in the Chinese general population, the prevalence of cardio-cerebrovascular disease was considerably higher. |
T83 |
7393-7666 |
Sentence |
denotes |
More importantly, the presence of diabetes, cardio-cerebrovascular disease and hypertension was associated with a 2-fold, 3-fold and 2-fold greater risk of severe disease or requiring intensive care unit (ICU) admission, suggesting prognostic impact of these comorbidities. |
T84 |
7667-7816 |
Sentence |
denotes |
A much larger report from the Chinese Center for Disease Control and Prevention described clinical outcomes in 44672 confirmed cases of COVID-19 [1]. |
T85 |
7817-7991 |
Sentence |
denotes |
The overall case fatality rate (CFR) was 2.3% in the entire cohort but significantly higher (6%, 7.3% and 10.5% respectively) in patients with hypertension, diabetes and CVD. |
T86 |
7992-8163 |
Sentence |
denotes |
Although data is lacking, the prevalence of various CV comorbidities and their impact on clinical outcomes seem to vary considerably across different geographic locations. |
T87 |
8164-8291 |
Sentence |
denotes |
The CFRs have been lower in China outside Hubei province and many other countries but much higher in some European nations [2]. |
T88 |
8292-8414 |
Sentence |
denotes |
A small report including 21 patients from Washington, United States of America presented a particularly grim scenario [9]. |
T89 |
8415-8526 |
Sentence |
denotes |
Comorbidities were common in this cohort, with diabetes present in 33.3% and congestive heart failure in 42.9%. |
T90 |
8527-8604 |
Sentence |
denotes |
Acute cardiac dysfunction occurred in 33.3% patients and 52.4% patients died. |
T91 |
8605-8844 |
Sentence |
denotes |
However, the overall CFR in the United States seems to be much lower (201 deaths out of 15219 confirmed cases) [2], although it is likely to rise as many of the patients are currently hospitalized and have not yet had the definite outcome. |
T92 |
8846-8892 |
Sentence |
denotes |
2.2 Cardiovascular manifestations of COVID-19 |
T93 |
8894-8924 |
Sentence |
denotes |
2.2.1 Acute myocardial injury |
T94 |
8925-9018 |
Sentence |
denotes |
Acute myocardial injury is the most commonly described CV complication in COVID-19 (Table 1). |
T95 |
9019-9210 |
Sentence |
denotes |
Different reports have used different definitions for acute myocardial injury, including rise in cardiac enzymes (different biomarkers and cut-offs) and/or electrocardiographic abnormalities. |
T96 |
9211-9367 |
Sentence |
denotes |
However, an elevation of high-sensitivity cardiac troponin I (cTnI) above 99th percentile upper reference limit is the most commonly used definition.Table 1 |
T97 |
9368-9528 |
Sentence |
denotes |
The overall incidence of acute cardiac injury has been variable but roughly 8–12% of the positive cases are known to develop significant elevation of cTnI [10]. |
T98 |
9529-9798 |
Sentence |
denotes |
The aforementioned meta-analysis of the Chinese studies [4] reported 8% incidence of acute cardiac injury whereas another study including only those patients who had had a definite outcome (death or discharge from hospital) reported 17% incidence of cTnI elevation [5]. |
T99 |
9799-9960 |
Sentence |
denotes |
Regardless of the actual incidence, acute cardiac injury has been consistently shown to be a strong negative prognostic marker in patients with COVID-19 [5,6,8]. |
T100 |
9961-10079 |
Sentence |
denotes |
The patients admitted to ICU or having severe/fatal illness have several-fold higher likelihood of troponin elevation. |
T101 |
10080-10218 |
Sentence |
denotes |
In contrast, the incidence of elevated troponin has been very low (only 1–2%) in patients having mild illness not requiring ICU admission. |
T102 |
10219-10346 |
Sentence |
denotes |
Any of the mechanisms described above can lead to acute cardiac injury and rise in cardiac troponins in patients with COVID-19. |
T103 |
10347-10571 |
Sentence |
denotes |
The relative role of these different mechanisms has not been described but direct (i.e. non-coronary) myocardial injury due to viral myocarditis or the effect of systemic inflammation appear to be the most common mechanisms. |
T104 |
10572-10708 |
Sentence |
denotes |
These observations are supported by a previous autopsy study in patients who had died due to SARS during the Toronto SARS outbreak [11]. |
T105 |
10709-10870 |
Sentence |
denotes |
In this study, the viral ribonucleic acid was detected in 35% of the autopsied human heart samples, providing evidence for direct myocardial injury by the virus. |
T106 |
10871-10992 |
Sentence |
denotes |
No study has described the incidence of ST-segment elevation myocardial infarction in COVID-19, but it appears to be low. |
T107 |
10993-11142 |
Sentence |
denotes |
Similarly, the incidence of left ventricular systolic dysfunction, acute left ventricular failure and cardiogenic shock have also not been described. |
T108 |
11143-11227 |
Sentence |
denotes |
Only one Chinese study reported incidence of heart failure in COVID-19 patients [5]. |
T109 |
11228-11365 |
Sentence |
denotes |
Heart failure had occurred in 52% of the patients who subsequently died and in 12% of the patients who were discharged from the hospital. |
T110 |
11367-11385 |
Sentence |
denotes |
2.2.2 Arrhythmias |
T111 |
11386-11451 |
Sentence |
denotes |
Both tachy- and brady-arrhythmias are known to occur in COVID-19. |
T112 |
11452-11582 |
Sentence |
denotes |
A study describing clinical profile and outcomes in 138 Chinese patients with COVID-19 reported 16.7% incidence of arrhythmia [8]. |
T113 |
11583-11710 |
Sentence |
denotes |
The incidence was much higher (44.4%) in those requiring ICU admission as compared to those not requiring ICU admission (8.9%). |
T114 |
11711-11752 |
Sentence |
denotes |
The type of arrhythmia was not described. |
T115 |
11754-11793 |
Sentence |
denotes |
2.2.3 Potential long-term consequences |
T116 |
11794-11932 |
Sentence |
denotes |
COVID-19 has emerged only a few months ago and it is too early to predict long-term outcome of the patients who recover from this illness. |
T117 |
11933-12090 |
Sentence |
denotes |
However, some important messages can be gleaned from previous experiences with SARS, caused by SARS-CoV which shares considerable similarity with SARS-CoV-2. |
T118 |
12091-12315 |
Sentence |
denotes |
It was reported that among patients who had recovered from SARS, 68% continued to have abnormalities of lipid metabolism at 12-years follow-up; CV abnormalities were present in 40% and altered glucose metabolism in 60% [12]. |
T119 |
12316-12425 |
Sentence |
denotes |
Similar findings have also been reported in patients recovering from other respiratory tract infections [13]. |
T120 |
12426-12629 |
Sentence |
denotes |
Considering this, careful follow-up of those recovering from the current COVID-19 would be important to understand the long-term impact of this illness and also to protect these patients from future CVD. |
T121 |
12631-12659 |
Sentence |
denotes |
2.3 Management implications |
T122 |
12660-12841 |
Sentence |
denotes |
The overall management principles for patients presenting with COVID-19 who develop CV complications or who have pre-existing CVD are same as for any other patient without COVID-19. |
T123 |
12842-12910 |
Sentence |
denotes |
However, there are a few important points that need consideration-1. |
T124 |
12911-13031 |
Sentence |
denotes |
As caregivers, it is our utmost responsibility to protect ourselves from getting infected while managing these patients. |
T125 |
13032-13156 |
Sentence |
denotes |
Therefore, all heathcare personnel engaged in the care of COVID-19 patients must observe necessary precautions at all times. |
T126 |
13157-13307 |
Sentence |
denotes |
All of them should be trained in donning, usage, and doffing of the personal protective equipment in accordance with the existing practice guidelines. |
T127 |
13308-13310 |
Sentence |
denotes |
2. |
T128 |
13311-13471 |
Sentence |
denotes |
The hospital systems need to ensure preparedness for dealing with large volume of COVID-19 patients, many of whom would need ICU care and/or acute cardiac care. |
T129 |
13472-13631 |
Sentence |
denotes |
Appropriate protocols for rapid diagnosis, triage, isolation, and management of COVID-19 patients with CV complications should be developed and well-rehearsed. |
T130 |
13632-13800 |
Sentence |
denotes |
Rapid triaging and management of these patients is crucial, not only to allow efficient utilization of healthcare resources but also to minimize exposure to caregivers. |
T131 |
13801-13955 |
Sentence |
denotes |
There are already reports highlighting delays in delivering acute cardiac care due to extra precautions that need to be observed in view of COVID-19 [14]. |
T132 |
13956-14003 |
Sentence |
denotes |
Efforts should be made to minimize such delays. |
T133 |
14004-14006 |
Sentence |
denotes |
3. |
T134 |
14007-14147 |
Sentence |
denotes |
Strong emphasis should be placed on avoiding unwarranted diagnostic tests (e.g. cardiac troponin, echocardiography, etc.) in these patients. |
T135 |
14148-14381 |
Sentence |
denotes |
This is required to minimize unwarranted downstream diagnostic/therapeutic procedures which would further strain the already stretched healthcare resources and would also subject caregivers to added risk of exposure to the infection. |
T136 |
14382-14544 |
Sentence |
denotes |
The American College of Cardiology has released an advisory discouraging random measurement of cardiac biomarkers such as troponins and natriuretic peptides [15]. |
T137 |
14545-14709 |
Sentence |
denotes |
It urges all the clinicians to reserve these assays for circumstances in which they would actually meaningfully add to the management of the patients with COVID-19. |
T138 |
14710-14847 |
Sentence |
denotes |
The American Society of Echocardiography has also issued a similar advisory regarding the use of echocardiography in these patients [16]. |
T139 |
14848-14850 |
Sentence |
denotes |
4. |
T140 |
14851-15062 |
Sentence |
denotes |
The individual hospitals may also have to reconsider risk-benefit ratio of primary percutaneous intervention vs fibrinolysis in patients with COVID-19 who present with ST-segment elevation myocardial infarction. |
T141 |
15063-15065 |
Sentence |
denotes |
5. |
T142 |
15066-15214 |
Sentence |
denotes |
There has been a concern regarding the safety of ACE inhibitors (ACEi) and angiotensin receptor blockers (ARB) during the ongoing COVID-19 pandemic. |
T143 |
15215-15311 |
Sentence |
denotes |
These agents upregulate expression of ACE2 in various tissues, including on cardiomyocytes [17]. |
T144 |
15312-15536 |
Sentence |
denotes |
Since SARS-CoV-2 binds to ACE2 to gain entry into human cells, there is a potentially increased risk of developing COVID-19 or developing more severe disease in patients who are already on background treatment with ACEi/ARB. |
T145 |
15537-15627 |
Sentence |
denotes |
However, to date, no experimental or clinical data have emerged to support these concerns. |
T146 |
15628-15704 |
Sentence |
denotes |
At the same time, the risks of discontinuing these therapies are well known. |
T147 |
15705-15883 |
Sentence |
denotes |
Therefore, several leading professional societies have strongly urged to not discontinue clinically-indicated ACEi/ARB therapy in the event the patient develops COVID-19 [18,19]. |
T148 |
15884-15886 |
Sentence |
denotes |
6. |
T149 |
15887-16044 |
Sentence |
denotes |
Clinicians caring for these patients also need to be fully aware of the potential CV side-effects of various therapies used for treating the viral infection. |
T150 |
16045-16206 |
Sentence |
denotes |
Additionally, various anti-retroviral drugs have significant interactions with cardiac drugs, which need to be considered and appropriate dose modification done. |
T151 |
16207-16358 |
Sentence |
denotes |
More recently, chloroquine/hydroxychloroquine and azathioprine have been proposed as potential therapeutic options, based on preliminary evidence [20]. |
T152 |
16359-16473 |
Sentence |
denotes |
Both these drugs are known to prolong QT interval and due caution must be exercised when prescribing these agents. |
T153 |
16474-16756 |
Sentence |
denotes |
Their combination is best avoided and even when using chloroquine/hydroxychloroquine alone, daily electrocardiogram for monitoring QT interval is warranted, esp. in patients with hepatic or renal dysfunction and in those receiving another drug with potential to prolong QT interval. |
T154 |
16758-16790 |
Sentence |
denotes |
3 Summary and future directions |
T155 |
16791-17068 |
Sentence |
denotes |
Although respiratory illness is the dominant clinical manifestation of COVID-19, the shear burden of the illness implies that a large number of patients with COVID-19 would present with pre-existing CVD or develop new-onset cardiac dysfunction during the course of the illness. |
T156 |
17069-17180 |
Sentence |
denotes |
Considering this, the current understanding about the interplay between CVD and COVID-19 is grossly inadequate. |
T157 |
17181-17381 |
Sentence |
denotes |
It is therefore highly desirable that the future studies on COVID-19 specifically describe the incidence, mechanisms, clinical presentation and outcomes of various CV manifestations in these patients. |
T158 |
17382-17507 |
Sentence |
denotes |
The diagnostic and therapeutic challenges posed by the concurrence of these two illnesses also need to be adequately studied. |